Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $10.5M | $22.1M | $29.2M | $35.4M | $39.8M | $52.4M | $55.9M | $67.2M |
| Cost of revenue | $3.7M | $8.9M | $12.7M | $16.3M | $19.4M | $26.1M | $30.2M | $33.4M |
| Gross profit | $6.9M | $13.2M | $16.5M | $19.0M | $20.4M | $26.2M | $25.7M | $33.9M |
| Gross margin | 65.3% | 59.6% | 56.5% | 53.8% | 51.3% | 50.1% | 46.0% | 50.4% |
| R&D | $988.9K | $1.5M | $1.7M | $2.3M | $2.7M | $3.4M | $1.3M | $3.9M |
| Operating income | $977.5K | $2.4M | $3.6M | $3.2M | $2.9M | $3.8M | $12.6M | $278.0K |
| EBITDA | $1.5M | $4.2M | $5.1M | $5.3M | $5.7M | $7.1M | $5.9M | $5.5M |
| Net income | $678.9K | $5.7M | $3.0M | $793.3K | $971.2K | $2.4M | $1.9M | −$607.0K |
| Net margin | 6.5% | 25.8% | 10.1% | 2.2% | 2.4% | 4.6% | 3.4% | -0.9% |
| EPS (diluted) | 0.01 | 0.05 | 0.02 | 0.01 | 0.01 | 0.02 | 0.01 | -0.00 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $95M | $0.08 | $0.08–$0.08 | 1 |
| 2027 | $105M | $0.09 | $0.09–$0.09 | 1 |
Forward consensus · source: Financial Modeling Prep
No one on the platform currently holds HTLZF.
No tracked institution reports a position in HTLZF as of their last filing.
No one on the platform has traded HTLZF yet.
| $255M |
| — |
| EKDHFEKF Diagnostics Holdings plc | $0.35 | +0.00% | $149M | — |
| FPHAFFaron Pharmaceuticals Oy | $3.30 | +0.00% | $210M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.